Greenland Mines Ltd. Common Stock (NASDAQ:GRML) Shares Gap Down – What’s Next?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) gapped down prior to trading on Monday . The stock had previously closed at $10.1350, but opened at $9.43. Greenland Mines Ltd. Common Stock shares last traded at $8.56, with a volume of 41,940 shares traded.

Analyst Ratings Changes

Several brokerages have commented on GRML. Wall Street Zen upgraded shares of Greenland Mines Ltd. Common Stock to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings downgraded Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Greenland Mines Ltd. Common Stock Price Performance

The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -28.22 and a beta of 7.13. The business has a fifty day moving average price of $0.22 and a 200 day moving average price of $0.35.

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) last issued its quarterly earnings data on Monday, August 17th. The company reported ($0.03) earnings per share for the quarter.

Insider Activity

In related news, Director Jason David Sawyer purchased 240,000 shares of Greenland Mines Ltd. Common Stock stock in a transaction dated Wednesday, July 22nd. The stock was bought at an average cost of $0.23 per share, with a total value of $55,200.00. Following the purchase, the director owned 240,000 shares in the company, valued at approximately $55,200. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Riad Hussein El-Dada sold 175,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $0.23, for a total transaction of $40,250.00. Following the completion of the transaction, the director owned 175,000 shares of the company’s stock, valued at $40,250. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 11.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Greenland Mines Ltd. Common Stock

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new position in Greenland Mines Ltd. Common Stock during the 2nd quarter valued at $26,000. XTX Topco Ltd increased its position in shares of Greenland Mines Ltd. Common Stock by 101.2% during the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock valued at $46,000 after purchasing an additional 80,768 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Greenland Mines Ltd. Common Stock in the 4th quarter worth $126,000. Geode Capital Management LLC raised its stake in shares of Greenland Mines Ltd. Common Stock by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after buying an additional 167,905 shares in the last quarter. Finally, Brummer Multi Strategy AB acquired a new stake in shares of Greenland Mines Ltd. Common Stock in the fourth quarter valued at $175,000. Institutional investors own 20.07% of the company’s stock.

Greenland Mines Ltd. Common Stock Company Profile

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.